Drug Profile
Research programme: ophthalmologic siRNA therapeutics - Sylentis
Alternative Names: SYL-040003; SYL-054003Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Sylentis
- Class Eye disorder therapies; Gene therapies; Small interfering RNA
- Mechanism of Action NRARP protein inhibitors; RNA interference; TRPV1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Age-related macular degeneration
- Discontinued Glaucoma; Ocular pain
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Spain (Ophthalmic, Drops)
- 03 May 2019 Sylentis plans a clinical trial for Age-related macular degeneration (Ophthalmic) in 2019
- 01 Apr 2018 Preclinical trials in Age-related macular degeneration in Spain (Ophthalmic, Drops), before April 2018